Reuters logo
BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission
October 20, 2017 / 12:51 PM / a month ago

BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission

Oct 20 (Reuters) - Azurrx Biopharma Inc:

* Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission

* Azurrx Biopharma - ‍IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below